Basic Information
| LncRNA/CircRNA Name | ZEB1-AS1 |
| Synonyms | NA |
| Region | GRCh38_10:31206278-31320447 |
| Ensemble | ENSG00000237036 |
| Refseq | NR_024284 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot etc |
| Sample | breast cancer tissues,cell lines (MCF-7 and MDA-MB-231) |
| Expression Pattern | up-regulated |
| Function Description | LncRNA ZEB1-AS1 was observed to be an upregulated lncRNA in breast cancer, and ZEB1 overexpression was noted in breast cancerous tissues. MiR-129-5p was revealed to specifically bind to both ZEB1 and lncRNA ZEB1-AS1. Moreover, the expression levels of ZEB1-AS1, ZEB1, Bcl-2, MDR-1, and corresponding proteins were decreased, but the expression of miR-129-5p was increased with transfection of miR-129-5p mimic and lncRNA ZEB1-AS1 siRNA. |
| Pubmed ID | 32210737 |
| Year | 2020 |
| Title | Inhibition of ZEB1-AS1 Confers Cisplatin Sensitivity in Breast Cancer by Promoting microRNA-129-5p-dependent ZEB1 Downregulation |
External Links
| Links for ZEB1-AS1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |